Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 244

Sort by

Sort Order Select

Journal Articles

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

Blood (2024) 144 (19): 2002–2017.

https://doi.org/10.1182/blood.2023022050

Published: 2024

Includes: Supplemental data

Journal Articles

Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia

Judith M. Boer, Marco J. Koudijs, Lennart A. Kester, Edwin Sonneveld, Jayne Y. Hehir-Kwa, Simone Snijder, Esmé Waanders, Arjan Buijs, Valerie de Haas, Inge M. van der Sluis, Rob Pieters, Monique L. den Boer, Bastiaan B.J. Tops

Blood (2024) 144 (Supplement 1): 1459.

https://doi.org/10.1182/blood-2024-193387

Published: 2024

Journal Articles

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

Shunsuke Kimura, Petri Pölönen, Lindsey Montefiori, Kenneth Caldwell, Ilaria Iacobucci, Chelsey Chen, Anthony Brown, Katie Han, Yen-Chun Liu, Yunchao Chang, Zhongshan Cheng, Zhou Yinmei, Chun Shik Park, Sharnise Mitchell, Noemi Reyes, Allen Yeoh, Andishe Attarbaschi, Andrew Moore, Atsushi Manabe, Barbara Buldini, Kean Hui Chiew, Chi Kong Li, Ching-Hon Pui, Chunxu Qu, Daisuke Tomizawa, Elisabeth Paietta, Franco Locatelli, Gabriele Escherich, Gao Qingsong, Hannah Elisa Muhle, Hanne Vibeke Marquart, Hester A. de Groot-Kruseman, Jacob M. Rowe, Jan Stary, Jan Trka, John Kim Choi, Jules P.P. Meijerink, Junko Takita, Katarzyna Pawinska-Wasikowska, Kjeld Schmiegelow, Mariko Eguchi, Martin Schrappe, Martin Zimmermann, Masatoshi Takagi, Melissa Maybury, Michael Svaton, Michaela Reiterova, Michal Kicinski, Motohiro Kato, Orietta Spinelli, Pauline Mazilier, Paul G. Thomas, Riccardo Masetti, Rishi Sury Kotecha, Rob Pieters, Sarah Elitzur, Selina M Luger, Shuhong Shen, Sima Jeha, Steven M. Kornblau, Szymon Skoczen, Takako Miyamura, Tiffaney Vincent, Toshihiko Imamura, Valentino Conter, Yanjing Tang, Zhaohui Gu, Kathryn G. Roberts, David T. Teachey, Kristine R Crews, Cheng Cheng, Jun J. Yang, Hiroto Inaba, Charles G. Mullighan

Blood (2023) 142 (Supplement 1): 845.

https://doi.org/10.1182/blood-2023-178688

Published: 2023

Journal Articles

The Effect of Immunoglobulin Prophylaxis on Infectious Morbidity in Pediatric Patients with Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial

Kirsten Thus, Hester A. de Groot-Kruseman, Pauline Winkler-Seinstra, Heidi Segers, Cor van den Bos, Inge M. Van Der Sluis, Wim Tissing, Margreet A. Veening, Michel C. Zwaan, Marta F. Fiocco, Cornelis van Tilburg, Rob Pieters, Marc Bierings

Blood (2023) 142 (Supplement 1): 2839.

https://doi.org/10.1182/blood-2023-173418

Published: 2023

Journal Articles

Implementation of Continuous Pegasparaginase Dosing without an Asparaginase-Free Interval Reduces Hypersensitivity in Children with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of the DCOG ALL11 Pegasparaginase Randomization

Leiah J. Brigitha, Rob Pieters, Marta F. Fiocco, Hester A. de Groot-Kruseman, Marc Bierings, Cor Van Den Bos, Valerie de Haas, Peter M. Hoogerbrugge, Wim J.E. Tissing, Margreet A. Veening, Inge M. Van Der Sluis

Blood (2023) 142 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2023-173359

Published: 2023

Journal Articles

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Blood (2023) 141 (7): 743–755.

https://doi.org/10.1182/blood.2022016975

Published: 2023

Includes: Supplemental data

Journal Articles

Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

Rob Pieters, Hester A. De Groot-Kruseman, Femke Verwer, Merian van Overveld, Edwin Sonneveld, Marta Fiocco, Vincent H.J. van der Velden, Berna Beverloo, Marc Bierings, Valerie De Haas, Peter M. Hoogerbrugge, Inge M. Van Der Sluis, Wim J.E. Tissing, Margreet Veening, Judith M. Boer, Monique L. den Boer

Blood (2022) 140 (Supplement 1): 519–520.

https://doi.org/10.1182/blood-2022-165931

Published: 2022

Journal Articles

The Prognostic Effect of IKZF1 Deletions in ETV6 :: RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Anna Østergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony V. Moorman, Judith M. Boer, Frank N van Leeuwen

Blood (2022) 140 (Supplement 1): 3483–3485.

https://doi.org/10.1182/blood-2022-157431

Published: 2022

Journal Articles

Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A -Rearranged Acute Lymphoblastic Leukemia Cells

Pauline Schneider, Susan T.C.J.M. Arentsen-Peters, Nicholas T. Crump, Alastair Smith, Rico Hagelaar, Fabienne R.S. Adriaanse, Romy S. Bos, Kirsten S. Vrenken, Dedeke rockx-Brouwer, Ziqin Tang, Wilbert P. Vermeij, Anja De Jong, Bianca Koopmans, M.Emmy M. Dolman, Thomas A. Milne, Rob Pieters, Ronald W. Stam

Blood (2022) 140 (Supplement 1): 8760–8761.

https://doi.org/10.1182/blood-2022-166310

Published: 2022

Journal Articles

Hydrocortisone or Placebo to Reduce Dexamethasone-Induced Neurobehavioral Side Effects: Results of a Phase 3 National, Double-Blind, Placebo-Controlled Randomized Trial with Crossover Design

Annelienke M. van Hulst, Erica L.T. van den Akker, Emma J. Verwaaijen, Marta Fiocco, Niki Rensen, Raphaële R.L. van Litsenburg, Saskia M.F. Pluijm, C. Michel Zwaan, Hanneke M. Van Santen, Rob Pieters, Andrea W.M. Evers, Martha A. Grootenhuis, Marry M. van den Heuvel-Eibrink

Blood (2022) 140 (Supplement 1): 3162–3163.

https://doi.org/10.1182/blood-2022-163329

Published: 2022

Journal Articles

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Blood (2022) 139 (12): 1785–1793.

https://doi.org/10.1182/blood.2021012328

Published: 2022

Includes: Supplemental data

Journal Articles

Fludarabine Exposure Predicts Outcome after CD19 CAR T Cell Therapy in Children and Young Adults with Acute Leukemia; An Exploratory, Observational Study

Blood (2021) 138 (Supplement 1): 3871.

https://doi.org/10.1182/blood-2021-146450

Published: 2021

Journal Articles

Influence of Bisphosphonates or Recombinant Human Parathyroid Hormone on in Vitro Chemotherapy Sensitivity in Acute Lymphoblastic Leukemia Cells

Demi T.C. de Winter, Jenneke E. van Atteveld, Jessica G.C.A.M. Buijs-Gladdines, Rob Pieters, Sebastian J.C.M.M. Neggers, Jules P.P. Meijerink, Marry M. van den Heuvel-Eibrink

Blood (2021) 138 (Supplement 1): 4355.

https://doi.org/10.1182/blood-2021-152430

Published: 2021

Journal Articles

A Meta-Analysis of Hypersensitivity to Pegylated Escherichia coli Asparaginase Used As First-Line Treatment in Contemporary Pediatric Acute Lymphoblastic Leukemia Protocols

Leiah Brigitha, Marta Fiocco, Rob Pieters, Birgitte Klug Albertsen, Gabriele Escherich, Elixabet Lopez-Lopez, Veerle Mondelaers, Ajay Vora, Lynda M. Vrooman, Kjeld Schmiegelow, Inge M. Van Der Sluis

Blood (2021) 138 (Supplement 1): 2308.

https://doi.org/10.1182/blood-2021-144674

Published: 2021

Journal Articles

Selective Inhibition of Class II HDAC Isoforms 4 and 5 Provides a Promising Therapeutic Intervention for MLL -Rearranged Acute Lymphoblastic Leukemia in Infants

Tamara C.A.I. Verbeek, Susan Arentsen-Peters, Patricia Garrido Castro, Sandra Pinhancos, Kirsten Vrenken, Aida Varela-Moreira, M. Emmy Dolman, Bianca Koopmans, Rob Pieters, Ronald W. Stam

Blood (2021) 138 (Supplement 1): 2206.

https://doi.org/10.1182/blood-2021-147164

Published: 2021

Journal Articles

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2021) 138 (Supplement 1): 2383.

https://doi.org/10.1182/blood-2021-145058

Published: 2021

Journal Articles

A Validated Risk Prediction Model for Bone Fragility in Children with Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2021-146838

Published: 2021

Journal Articles

A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A -Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network

Inge M. Van Der Sluis, Paola De Lorenzo, Rishi Sury Kotecha, Andishe Attarbaschi, Gabriele Escherich, Karsten Nysom, Jan Stary, Alina Ferster, Benoit Brethon, Phillip Ancliff, Andrea Biondi, Maria Grazia Valsecchi, Rob Pieters

Blood (2021) 138 (Supplement 1): 361.

https://doi.org/10.1182/blood-2021-144843

Published: 2021

Journal Articles

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134303

Published: 2020

Journal Articles

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Valentina Cordo', MSc, Donna Debets, MSc, Willem K. Smits, Zhongli Chen, MSc, Jelle Dylus, Guido Zaman, PhD, Maarten Altelaar, PhD, Koichi Oshima, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Jan Cools, PhD, Adolfo A. Ferrando, MD PhD, Josef Vormoor, MD PhD, Rob Pieters, MDPhDMSc, Britta Julia Vormoor, MD, Jules P.P. Meijerink, PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-139305

Published: 2020

NARROW

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

The Effect of Immunoglobulin Prophylaxis on Infectious Morbidity in Pediatric Patients with Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial

Implementation of Continuous Pegasparaginase Dosing without an Asparaginase-Free Interval Reduces Hypersensitivity in Children with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of the DCOG ALL11 Pegasparaginase Randomization

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

The Prognostic Effect of IKZF1 Deletions in ETV6 :: RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A -Rearranged Acute Lymphoblastic Leukemia Cells

Hydrocortisone or Placebo to Reduce Dexamethasone-Induced Neurobehavioral Side Effects: Results of a Phase 3 National, Double-Blind, Placebo-Controlled Randomized Trial with Crossover Design

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Fludarabine Exposure Predicts Outcome after CD19 CAR T Cell Therapy in Children and Young Adults with Acute Leukemia; An Exploratory, Observational Study

Influence of Bisphosphonates or Recombinant Human Parathyroid Hormone on in Vitro Chemotherapy Sensitivity in Acute Lymphoblastic Leukemia Cells

A Meta-Analysis of Hypersensitivity to Pegylated Escherichia coli Asparaginase Used As First-Line Treatment in Contemporary Pediatric Acute Lymphoblastic Leukemia Protocols

Selective Inhibition of Class II HDAC Isoforms 4 and 5 Provides a Promising Therapeutic Intervention for MLL -Rearranged Acute Lymphoblastic Leukemia in Infants

Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

A Validated Risk Prediction Model for Bone Fragility in Children with Acute Lymphoblastic Leukemia

A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A -Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only